在类风湿性关节炎中更新托西利祖马布:叙述性综述
Simone Parisi1, Maria Chiara Ditto1, Francesco Ghellere1
1Rheumatology Unit, Azienda Ospedaliera Universitaria Città della Salute e della Scienza di Torino, Turin, Italy.
Frontiers in immunology
|March 11, 2025
概括
托西利祖马布 (TCZ) 通过向IL-6受体,有效治疗类风湿性关节炎 (RA). 临床试验和现实世界的数据都证实了其长期持续的疗效和安全性.
科学领域:
- 类风湿病学 类风湿病学
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 类风湿性关节炎 (RA) 是一种普遍的慢性炎症状况,影响关节.
- 托西利祖马布 (TCZ) 是一种IL-6受体抑制剂,是 RA 管理的关键治疗剂.
研究的目的:
- 为提供托西利祖马布在类风湿性关节炎中疗效和安全性的最新审查.
- 综合来自随机对照试验 (RCT) 和现实世界证据 (RWE) 的数据.
主要方法:
- 对关键临床试验 (SAMURAI,OPTION,RADIATE,TOWARD) 和长期研究 (STREAM) 的审查.
- 对现实世界证据 (RWE) 的分析,以确定反应预测因素和患者适应性.
- 评估安全数据,包括心血管影响,脂质概况和感染风险.
主要成果:
- TCZ在RA中显示出显著的疗效,无论是单独治疗还是与csDMARDs一起使用,特别是在对其他治疗不耐药的患者中.
- 长期研究证实了TCZ在5年内持续有效性和良好的安全性.
- RWE支持TCZ的有效性,强调其在生物素素和超重人群中的实用性,心血管风险没有显著增加.
结论:
- 托西利祖马布是类风湿性关节炎的关键治疗方法,得到了强大的临床和现实世界的数据的支持.
- TCZ为各种RA患者群体提供了成熟的安全性和有效性概况.
- 对于TCZ使用的特殊考虑包括与RA相关的间歇性肺病和粉症.
相关概念视频
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
107
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
107
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
130
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
130
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
92
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
92
01:29Inflammatory Bowel Disease IV: Pharmacological Management
86
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
86
01:24T Cell Types and Functions
756
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
756
01:29Drugs for Treatment of Ulcerative Colitis in IBD
116
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
116